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Abstract
Protein tyrosine kinase-7 (PTK7) is a catalytically inactive receptor tyrosine kinase (RTK). PTK7 is upregulated in many
common human cancers, including colon cancer, lung cancer, gastric cancer and acute myeloid leukemia. The reason for
this up-regulation is not yet known. To explore the functional role of PTK7, the expression of PTK7 in HCT 116 cells was
examined using small interference (siRNA)-mediated gene silencing. Following transfection, the siRNA successfully
suppressed PTK7 mRNA and protein expression. Knocking down of PTK7 in HCT 116 cells inhibited cell proliferation
compared to control groups and induced apoptosis. Furthermore, this apoptosis was characterized by decreased
mitochondrial membrane potential and activation of caspase-9 and -10. Addition of a caspase-10 inhibitor totally blocked
this apoptosis, suggesting that caspase-10 may play a critical role in PTK7-knockdown-induced apoptosis, downstream of
mitochondria. These observations may indicate a role for PTK7 in cell proliferation and cell apoptosis and may provide a
potential therapeutic pathway for the treatment of a variety of cancers.
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Introduction
Receptor tyrosine kinases (RTKs) compose a class of transmem-
brane signaling proteins that transmit extracellular signals to the
interior of the cell. Misregulation of RTKs plays an important role
inthe developmentand/orprogressionofmanyformsofcancer[1].
Protein tyrosine kinase-7 (PTK7), which is also known as colon
carcinoma kinase-4 (CCK4), is a relatively new and little studied
member of the RTK superfamily. It contains an extracellular
domain with seven immunoglobulin-like loops, a transmembrane
domain, and a catalytically inactive tyrosine kinase domain [2,3].
However, as a result of an amino acid substitution within the
catalytic domain, PTK7 is a pseudokinase without detectable
catalytictyrosinekinaseactivity[1,4].Itwasoriginallyidentified asa
gene-expressed colon cancer-derived cell line, but it is not expressed
in human adult colon tissues [2]. In contrast, high levels of PTK7
expression are seen in fetal mouse colons [1,2,4]. The expression of
PTK7 is up-regulated in many common human cancers, including
colon cancer, lung cancer, gastric cancer and acute myeloid
leukemia [2,5,6,7,8,9]. Recently, PTK7 was identified as a novel
regulator of non-canonical WNT or planar cell polarity (PCP)
signaling [10,11]. PTK7 also appears to play an important role in
tube formation, migration, invasion of endothelia and angiogenesis
in HUVEC cells [12]. However, the functional role of PTK7 in cell
proliferation and apoptosis remains unclear.
Aptotosis is programmed cell death, typically mediated by a
family of cysteine proteases known as caspases [13]. Caspases are
synthesized as inactive proenzymes with either a long (caspase-8, -9
and -10) or a short (caspase-3, -6 and -7) prodomain [14,15]. These
latter proteases cleave a series of essential intracellular proteins
leading to cell death [16].
Two main apoptosis pathways have been identified. The
intrinsic pathway (mitochondria pathway) involves a decrease in
mitochondrial membrane potential and release of cytochrome
c[17], which activates caspase-9 through the apoptosome. Then,
caspase-9 initiates a proteolytic caspase cascade that kills the cells.
The extrinsic pathway (death receptor pathway) involves the
tumor necrosis factor (TNF) receptor superfamily. In response to
TNF ligand binding, these membrane receptors recruit adapter
molecules and activate caspase-8 in the death-inducing signaling
complex (DISC). Activated caspase-8 either directly activates
downstream effector caspases, such as caspase-3, or connects to the
intrinsic pathway through cleavage of BCL-2 Interacting Domain
(Bid) to truncated Bid (tBid)[18].
The caspase-10 gene is linked to the caspase-8 gene at the
human chromosome locus 2q33-34 [19]. However, the physio-
logical functions of caspase-10 remain poorly understood,
although it is thought to play a role in the death receptor
pathway. Caspase-10 was also reported to be activated down-
stream of the mitochondria in cytotoxic drug-induced apoptosis of
tumor cells [20]. Acquired inactivating mutations of caspase-10
have been identified in tumor cells from patients with solid tumors
[21,22,23]. Recently, caspase-10 was shown to play a role in
apoptosis induced by paclitaxel, an anticancer drug, through a
Fas-Associated protein with Death Domain (FADD) -dependent
mechanism [24].
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[25] in their work on Caenorhabditis elegans. RNAi is a cellular
mechanism by which small interfering RNAs (siRNAs) (19-23
nucleotides in length) trigger the degradation of specific mRNA
[25,26]. It has been demonstrated that siRNAs can silence cognate
gene expression via the RNAi pathway in mammalian cells [27].
The properties of RNAi, including stringent target-gene specificity
and simplicity of design and testing [28], have greatly widened its
potential for mechanistic studies of proteins, as well as for
therapeutic approaches to treat diseases, including cancer [29,30].
In this study, a siRNA targeting human PTK7 mRNA was used
for maximal inhibition of PTK7 expression in order to probe the
role of PTK7 in apoptosis and proliferation. Knocking down
PTK7 in HCT 116 cells inhibited cell proliferation and induced
apoptosis. Furthermore, this apoptosis was characterized by
decreased mitochondrial membrane potential and activation of
caspase-9 and -10. Addition of a caspase-10 inhibitor totally
blocked this apoptosis, suggesting that caspase-10 may play a
critical role in PTK7-knockdown-induced apoptosis downstream
of mitochondria. Therefore, these observations may indicate a role
for PTK7 in cell proliferation and cell apoptosis.
Materials and Methods
Materials
McCoy’s 5A media were purchased from ATCC; fetal bovine
serum (FBS) (heat inactivated) was purchased from GIBCO, and
penicillin-streptomycin was purchased from Cellgro. Micro-Fast-
Track 2.0 Kit was purchased from Invitrogen. A colorimetric
bromodeoxyuridine (BrdU) kit was from BD Pharmingen. IScript
One-Step RT-PCR Kit with SYBR Green was from Biorad.
Protease inhibitor cocktail (mixture of 4-(2-aminoethyl)benzene-
sulfonyl fluoride (AEBSF), E-64, bestatin, leupeptin, aprotinin, and
sodium EDTA) and 0.4% trypan blue were from Sigma. The
protein assay kit was from Bio-Rad. Antibodies against caspase-9
and b-actin were from Cell Signaling Technology. Antibody
against caspase-10 was from Millipore. Antibody against PTK7
was from Abnova. Goat anti-mouse IgG HRP-conjugated
secondary antibody and goat anti-rabbit IgG HRP-conjugated
secondary antibody were purchased from Cell Signaling Tech-
nology. Vybrant Apoptosis Assay Kit #2, 46 NuPAGE LDS
sample buffer, 4–12% NuPAGE Bis-Tris gels, 206 NuPAGE
MOPS SDS running buffer, and 206 NuPAGE transfer buffer
were from Invitrogen. Immobilon-P transfer membrane was from
Millipore. SuperSignal West Dura Extended-Duration Substrate
and Restore plus Western blot Stripping buffer were from Thermo
Scientific. X-ray films were from ISCBioExpress. JC-1 (5,59,6,69-
tetrachloro-1,19,3,39- tetraethylbenzimidazolylcarbocyanine io-
dide) was purchased from Anaspec. Caspase-9 inhibitor (Z-
LEHD-FMK), caspase-3 inhibitor (Z-DEVD-FMK), caspase-8
inhibitor (Z-IETD-FMK), caspase-family inhibitor (Z-VAD-
FMK), caspase-1 inhibitor (Z-YVAD-FMK), caspase-10 inhibitor
(Z-AEVD-FMK) and caspase-2 inhibitor (Z-VDVAD-FMK) were
purchased from BioVision. Caspase-10 Fluorometric Protease
Assay Kit was from Millipore.
Cell Culture
HCT 116 (colon carcinoma) cells were obtained from ATCC
(Manassas, VA) and maintained in tissue culture at 37uC and 5%
CO2. p53-null HCT 116 cells were provided by Dr. Bert
Vogelstein (The Johns Hopkins Kimmel Cancer Center). Cells
were cultured in McCoy’s 5A medium supplemented with 10%
fetal bovine serum (FBS) (heat inactivated) and 100 IU/mL
penicillin-streptomycin.
RNA interference
HiPerFect transfection reagent, HP-validated siRNA specific for
PTK7, named PTK7 siRNA (sense: 59- CGGGATGATGT-
CACTGGAGAA-39), and a nonspecific siRNA (AllStars Negative
Control siRNA) were purchased from Qiagen. HCT 116 cells
were transfected with siRNA by HiPerFect transfection reagent.
On day 1, cells in exponential growth phase were harvested and
suspended in growth medium. Cells were divided into four groups
and were treated with PTK7 siRNA, a nonspecific siRNA as
negative control, HiPerFect vehicle only, or were left untreated.
For each transfection, a 500 mL cell suspension was transfected
with 25 nM siRNA using 4 mL transfection reagent in 24-well
plates. Cells were kept in normal culture conditions and collected
2, 3 or 4 days after transfection for analysis.
Flow Cytometric Analysis
After transfection with siRNAs as described above, cells were
trypsinized, washed twice in PBS, and counted using a
hemocytometer. Aliquots of 5610
5 cells were incubated with
excess phycoerythring (PE)-labeled anti-PTK7 in 200 mLo f
binding buffer (PBS containing 5 mM MgCl2, 4.5 mg/mL
glucose, 0.1 mg/mL yeast tRNA, 1 mg/mL BSA and 20% FBS)
on ice for 30 min. Cells were then washed twice with 1 mL of
binding buffer and suspended in 0.3 mL of binding buffer. The
fluorescence was determined with a FACScan cytometer (Becton
Dickinson Immunocytometry Systems, San Jose, CA). PE-labeled
anti-IgG was used as a negative control.
Quantitative RT-PCR
Total mRNA from cells treated with various siRNAs was
extracted with Micro-FastTrack 2.0 Kit according to the
manufacturer’s instructions. Real-time PCR was performed on
mRNA (50 ng) with iScript One-Step RT-PCR Kit using SYBR
Green with a Biorad iCycler. All reactions were performed in a 50-
mL volume in triplicate. Primers for human PTK7 were purchased
from Qiagen (QT00015568). PCR parameters were as follows:
50uC for 30 min, 5 min of Taq activation at 95uC, followed by 45
cycles of PCR: 95uC630 s, 57uC660 s, and 72uC660 s. The
relative amount of target mRNA was normalized to GAPDH
mRNA. Specificity was verified by melting curve analysis. Means
and standard errors of at least three replicates of each experiment
are calculated. Significance was determined by t-test, a p
value#0.05 indicated by an asterisk.
Cell Number detection by Trypan Blue Exclusion Assay
For four days after treatment, cell suspensions were prepared by
trypsinization, and cells were resuspended in 1 mL media. To
25 mL of the cell suspension, 25 mL of 0.4% trypan blue was
added, and cells were counted using a hemocytometer.
Proliferation Assay
Cell proliferation was studied using a colorimetric bromode-
oxyuridine (BrdU) kit according to the manufacturer’s instructions.
First, cells were transfected with siRNA. After 48 h of treatment,
10 mM BrdU solution was added to the medium. The medium was
discarded after 2 h, and cells were fixed and permeabilized with
BD Cytofix/Cytoperm Buffer for 30 min at room temperature.
After removing Cytofix/Cytoperm Buffer, cells were incubated
with 100 mL of diluted DNase (diluted to 300 mg/mL in PBS) for
1 hour at 37uC to expose incorporated BrdU. Cells were then
resuspended in 50 mL of BD Perm/Wash Buffer containing
diluted FITC-labeled anti-BrdU and incubated for 20 minutes at
room temperature. Finally, cells were incubated with 20 mL of the
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and standard errors of at least three replicates of each experiment
were calculated. Significance was determined by t-test; a p
value#0.05 is indicated by an asterisk.
Annexin V/Propidium Iodide Double-Staining Assay
Annexin V/propidium iodide (PI) double-staining was performed
using the Invitrogen Vybrant Apoptosis Assay Kit #2. Cells were
washed twice in ice-cold PBS buffer and centrifuged at 900 rpm for
3 min. The pellets were resuspended in binding buffer at a density of
10
6 cells/mL. A sample solution (100 mL) was double-stained with
5 mL Annexin V/Alexa Fluor 488 and 2 mL1 0 0mg/mL PI. After
incubation at room temperature for 15 min, 400 mLo fb i n d i n g
buffer was added, and cells were analyzed by flow cytometry.
Western Blot Analyses
After HCT 116 cells were transfected with PTK7 siRNA for
12 h, 24 h, 30 h, and 48 h, whole cells were harvested and washed
twice with ice-cold PBS. Then cells were lysed in radioimmuno-
precipitation buffer (150 mM NaCl, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 50 mM Tris-
HCl, pH 7.5, and 2 mM EDTA) in the presence of proteinase
inhibitor cocktail for 20 min on ice. Lysates were centrifuged at
14,000 rpm for 20 min at 4uC, and the protein content in the
supernatant was measured using the Bio-Rad protein assay. Fifty
micrograms of supernatant proteins were mixed with 46NuPAGE
LDS sample buffer and heated at 70uC for 10 min. The proteins
wereseparatedon4–12%NuPAGEBis-Trisgelswith16NuPAGE
MOPS SDS running buffer and then electrotransferred onto a
PVDF transfermembranewithNuPAGEtransferbufferat50 V for
1 h. The membranes were blocked with 5% nonfat dry milk in PBS
buffer containing 0.2% Tween 20 (PBST) for 2 h at room
temperature. The membranes were probed withprimary antibodies
in PBST containing 5% nonfat dry milk overnight at 4uC. After
three successive washings with PBST for 10 min, the membranes
were incubated with horseradish peroxidase-conjugated goat anti-
mouse IgG antibody or goat anti-rabbit IgG antibody in PBST
containing 5% nonfat dry milk for 1 h at room temperature. After
three successive washings with PBST for 10 min, the proteins
signals were developed with a SuperSignal West Dura Extended
Duration Substrate kitand transferredfromthemembranetoX-ray
films. Protein loading was normalized by probing the same
membrane with anti-actin antibody. For b-actin detection,
previously used membranes were soaked in Restore Plus Western
Blot Stripping Buffer at room temperature for 30 min and
hybridized with anti-b actin.
Measurement of Mitochondrial Membrane Potential
Dye JC-1 (5,59,6,69-tetrachloro-1,19,3,39- tetraethylbenzimida-
zolylcarbocyanine iodide) was used to determine mitochondrial
membrane potential (DYm), the loss of which is regarded as a
crucial step in the apoptosis pathway. HCT 116 cells were
transfected with siRNA for 48 h or 72 h, after which the cells were
washed with cold PBS and stained by incubating with 2 mM JC-1
for 20 min at 37uC. Then, the mitochondrial membrane potential
was detected by fluorescence microscopy and flow cytometry at
590 nm.
Caspase-10 Activity Measurement
Caspase-10 activity was measured using the Caspase-10
Fluorometic Protease Assay Kit. Briefly, cells were transfected
with PTK7 siRNA, and after 24 h or 48 h cells were harvested.
Two million cells were resuspended in chilled lysis buffer and
incubated on ice for 10 min. Then, 50 mLo f2 6Reaction Buffer
and 5 mL of the 1 mM AEVD-AFC substrate (50 mM final
concentration) were added to each sample. After incubation at
37uC for 2 h, samples were analyzed using a microplate reader
equipped with a 400 nm excitation filter and a 505 nm emission
filter. Means and standard errors of at least three replicates of each
experiment were calculated. Significance was determined by t-test,
a p value#0.05 is indicated by an asterisk.
Results
Inhibition of PTK7 expression by PTK7 siRNA
Expression of PTK7 in HCT 116, human colon carcinoma
cells, was investigated by flow cytometry (Fig. 1A, untreated) and
Western blot (Fig. 1B, 0 h). Comparing the fluorescence signal of
PE-labeled anti-PTK7 to PE-labeled anti-mouse IgG clearly shows
that PTK7 is expressed in HCT 116 cells.
Expression of PTK7 was knocked down using PTK7-targeted
siRNA and the flow cytometry results for the targeted cells were
compared to those exposed to vehicle only, nonspecific siRNA or
untreated, as shown in Fig. 1A. After 48 hours, the peak of anti-
PTK7-PEinHCT116transfectedwithPTK7siRNAshiftedbackto
the peak of the background control protein, anti-IgG-PE, indicating
that the PTK7 expression level in HCT 116 cells transfected with
PTK7 siRNA greatly decreased. At the same time, there was no
corresponding shift in the control siRNA or vehicle-treated groups,
indicating that neither the HiPerFect transfection reagent nor the
nonspecific siRNA affected PTK7 expression. When PTK7
expressionwasprobedafter12 h,24 h,30 hand48 hoftransfection
using Western blot (Fig. 1B), the results clearly showed that the level
of PTK7 expression decreased after 48 h of transfection. In addition,
total mRNA was extracted from the untreated, vehicle, nonspecific
siRNA, and PTK7 siRNA groups. As shown in Fig. 1C, PTK7
siRNA induced 75–80% reduction of PTK7 mRNA in HCT 116
cells. These results indicated that both PTK7 protein and mRNA
expression levels were greatly decreased by PTK7 siRNA. This
proved the function and efficiency of PTK7 siRNA and provided a
solid basis for our study of PTK7’s functional role.
Viability and proliferation of PTK7 siRNA-treated HCT 116
cells
The effect of PTK7 suppression on the viability of HCT 116 cells
was investigated by counting the total number of live cells every day
after transfection.As shown inFig.2A,the numberof live HCT116
cells transfected with PTK7 siRNA was shown to be significantly
different from that of untreated groups on day 4. This finding
demonstrated a significant inhibition of cell viability in the HCT
116cellstreatedwith PTK7siRNA.To confirm that thedecrease of
cell viability resulted from suppression of PTK7, the same assays
were carried out with HCT 116 cells transfected with nonspecific
siRNA or treated only with vehicle. The results showed that the
PTK7 siRNA-treated sample contained the smallest number of
cells. Although vehicle-treated and nonspecific siRNA-treated cells
had smaller cell numbers than untreated cells, there were
significantly fewer cells in the PTK7 siRNA-treated sample.
To ascertain the effect of suppression of PTK7 on HCT 116 cell
proliferation, a BrdU incorporation experiment was performed to
measure DNA synthesis. After 48 h of transfection, cells were
seeded in 24-well culture plates and were incubated with 10 mM
BrdU for 2 h. Cells were then fixed, and BrdU incorporation was
detected using a FITC-labeled anti-BrdU antibody (Fig. 2B).
Silencing of PTK7 significantly inhibited BrdU incorporation in
HCT 116 cells, suggesting a direct effect of PTK7 protein on HCT
116 cell proliferation.
Silencing of PTK7
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An Annexin V/PI staining experiment was carried out to study
the possibility that knocking down PTK7 could affect the apoptosis
of HCT 116 cells. Phosphatidylserine (PS) is located in the inner
leaflet of the cell membrane in healthy cells. During apoptosis, PS
becomes translocated to the outer surface of the cell membrane,
and Annexin V/PI assay detects the PS on the outer surface. The
results in Figure 2C show that the PTK7 siRNA group showed
significant increase in apoptotic cells on day 4 compared with
untreated, vehicle, and nonspecific siRNA control groups.
Changes in mitochondrial membrane potential and
activation of caspase-9 in HCT 116 cells treated with
PTK7 siRNA
To study the mechanism through which knocking down PTK7
induces apoptosis in HCT 116 cells, the effect of knocking down PTK7
on mitochondrial membrane potential (DYm) was determined by
fluorescence microscopy (Fig. 3A) and flow cytometry (Fig. 3B). Dye
JC-1 was used as an indicator. In healthy cells, polarized mitochondria
have a negative charge, which allows JC-1 dye with delocalized positive
charge to enter the mitochondrial matrix and accumulate there. When
the critical concentration is exceeded, JC-1 forms J-aggregates, and the
Figure 1. PTK7 expression in HCT 116 cells after treatment with vehicle, nonspecific siRNA and PTK7 siRNA. (A) Flow cytometry assay
for the binding of the PE-labeled anti-PTK7 with HCT 116 cells (Grey curves). The black curves represent the background binding of anti-IgG-PE. The
concentration of the antibody in the binding buffer was 2 mg/mL. (B) Western blot analysis of PTK7 in HCT 116 cells transfected by PTK7 siRNAs. The
membrane was stripped and reprobed by b-actin antibody as a loading control. (C) Suppression of PTK7 mRNA expression in HCT 116 cells by PTK7
siRNAs. Cells were harvested after 48 h of treatment. RT-PCR was performed using gene-specific primers. The amount of PTK7 mRNA expression was
normalized to the untreated group. Data are mean6s.d. of three independent experiments. *Student’s t-test: P,0.05.
doi:10.1371/journal.pone.0014018.g001
Silencing of PTK7
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membrane potential collapses, and JC-1 cannot accumulate within the
mitochondria. In these apoptotic cells, JC-1 remains in the cytoplasm
in a green fluorescent monomeric form (FL1). After HCT 116 cells
were transfected with siRNA or control as described above and
incubated for 48 h or 72 h, the decrease of DYm in HCT 116 cells
transfected withPTK7 siRNA wasobserved.After72 hof transfection,
the percentage of cells with polarized mitochondria was 90%, 87% and
88% for cells in the untreated, vehicle and nonspecific siRNA groups,
respectively. However, only 35% of total cells in the PTK7 siRNA
Figure 2. Cell viability in HCT 116 cells after treatment with vehicle, nonspecific siRNA and PTK7 siRNA. Data are mean6s.d. of three
independent experiments. (A) The number of live cells was counted daily for 4 days using Trypan blue. (B) BrdU incorporation relative to untreated cells
detectedbyflowcytometry.Cells wereincubatedwith 10 mM BrdU for2 h after48 h of treatment.Theamount of BrdU incorporationwasnormalizedto
the untreated group. Data are mean6s.d. of three independent experiments. *Student’s t-test: P,0.05. (C) Apoptosis occurrence in HCT 116 cells
detected by Annexin V/PI stain on days 1–4 after transfection. Cells stained negative for both Annexin V and PI were considered healthy.
doi:10.1371/journal.pone.0014018.g002
Figure 3. Involvement of mitochondrial pathway in apoptosis induced by PTK7 scilencing. (A) Fluorescence microscope detection of
mitochondrial membrane potential intreated HCT 116 cells. (B) Flow cytometry detectionof mitochondrial membrane potential intreated HCT 116cells. (C) Activation
of caspase-9 involved in apoptosis induced by knocking down PTK7. The membrane was stripped and reprobed by b-actin antibody, as a loading control.
doi:10.1371/journal.pone.0014018.g003
Silencing of PTK7
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when only 58% cells had polarized mitochondria. These data
suggested that mitochondrial dysfunction was involved in the apoptosis
induced by PTK7 knockdown.
A variety of signalling pathways may be involved in apoptosis,
and the mitochondria play a major role. Mitochondrial dysfunc-
tion causes the release of cytochrome c, which activates caspase-9,
in turn fueling apoptosis. Caspase-9 activation was detected by
Western blot after HCT 116 cells were transfected with PTK7
siRNA and cultured for 12 h, 24 h, 30 h, and 48 h, respectively.
As shown in Figure 3C, caspase-9 was activated and involved in
the apoptosis induced by PTK7 knockdown.
Role of caspase-10 in PTK7-knockdown-induced
apoptosis
To determine whether caspases mediate the apoptosis induced by
knock down of PTK7, cells were pretreated with a pancaspase
inhibitor or one of several single-caspase-specificinhibitors.Rescue of
the cells from apoptosis would mean that the inhibited caspase was
implicated in PTK7-deficient cell death. After pre-incubation of the
HCT 116 cells with 20 mM pancaspase-family inhibitor at 37uCf o r
3 h, the cells were transfected with siRNA for 48 h. After incubation
for 48 h, cell viability was tested using Annexin V/PI (Fig. 4A). Cells
pre-incubated with pancaspase-family inhibitor showed good cell
viability (80613%) after transfection with PTK7 siRNA, within
Figure 4. Cell viability after incubation with caspase inhibitors prior to transfaction of PTK7 siRNA. (A) Apoptosis induced by knocking
down PTK7 was caspase-dependent. Data are mean6s.d. of three independent experiments. *Student’s t-test: P,0.05. (B) Caspase-10 inhibitor totally
blocked the apoptosis induced by knock down of PTK7. Data: mean6s.d. of three independent experiments, *Student’s t-test: P,0.05.
doi:10.1371/journal.pone.0014018.g004
Silencing of PTK7
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(8367.5%). Meanwhile, cells directly transfected with PTK7 siRNA
had significantly lower cell viability (36612%). Pancaspase-family
inhibitor blocked caspase activity and also blocked apoptosis induced
by knock down of PTK7, indicating that the apoptosis induced by
knock down of PTK7 is caspase-dependent.
To investigate which caspase plays the critical role in this
apoptosis, HCT 116 cells were pre-treated with caspase-9 inhibitor
(Z-LEHD-FMK), caspase-3 inhibitor (Z-DEVD-FMK), caspase-8
inhibitor (Z-IETD-FMK), caspase-family inhibitor (Z-VAD-
FMK), caspase-1 inhibitor (Z-YVAD-FMK), caspase-10 inhibitor
(Z-AEVD-FMK), caspase-2 inhibitor (Z-VDVAD-FMK), or
DMSO vehicle at 37uC for 3 h, followed by transfection with
PTK7 siRNA. After incubation for 48 h, cell viability was tested
by Annexin V/PI using flow cytometry. As shown in Fig. 4B,
inhibition of caspase-10 blocked apoptosis, with 7963% of cells
viable. This meant that caspse-10 may play a critical role in the
apoptotic pathway induced by knock down of PTK7.
To confirm the activation of caspase-10 in apoptosis induced by
PTK7 knockdown, procaspase-10 protein levels in cell lysates
transfected with PTK7 siRNA were examined using Western blot
(Fig. 5A). Procaspase-10 decreased after 12 h of transfection and
increased after 30 h of transfection. Also, as the linkage between the
intrinsic pathway and the extrinsic pathway, the cleavage of Bid to
tBid was investigated, and there was no obvious tBid, indicating that
there was no signal transfer from the extrinsic pathway to the
intrinsic pathway. In another experiment, PTK7 expression in HCT
116 was initially suppressed using PTK7 siRNA, resulting in
apoptosis in these cells. The ability of cell lysates to cleave the
peptide substrates (Ac-AEVD-AFC) was tested as an indicator of
caspase-10 activity. The results in figure 5B show significant increase
in caspase 10 activity in cells treated with PTK7 siRNA.
Figure 5. The activation of caspase-10 in apoptosis induced by knocking down of PTK7. (A) Western blot analysis of procaspase-10 and
Bid in HCT 116 cells transfected by PTK7 siRNAs. The membrane was stripped and reprobed by b-actin antibody, as a loading control. (B) Caspase-10
activity in HCT 116 cells: untreated and treated with vehicle, nonspecific siRNA and siRNA. Results were given as ratios to caspase-10 activity in
untreated cells. Data are mean6s.d. of three independent experiments. *Student’s t-test: P,0.05.
doi:10.1371/journal.pone.0014018.g005
Silencing of PTK7
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apoptosis
Protein p53 has been proved as a tumor suppressor protein in
humans[31], and HCT 116 cells express wide-type p53.[32,33] In
order to study the involvement of p53 in the apoptosis induced by
PTK7 knockdown, p53-null HCT 116 was used as the second cell line
to carry out PTK7 knockdown and other related experiments. First,
the PTK7 expression level without/with siRNA treatment was
monitored by flow cytometry (Fig. 6A). The p53-null HCT 116 cells
express a high amount of PTK7 on the cell membrane, but after
48 hours of PTK7 siRNA transfection, the peak for anti-PTK7-PE in
p53-null HCT 116 shifted back to the peak of the background control
protein, anti-IgG-PE. This indicated that the PTK7 expression level in
p53-null HCT 116 cells transfected with PTK7 siRNA was greatly
decreased.Next,the numberof live p53-nullHCT 116 cellstransfected
with PTK7 siRNA was shown to be significantly different from that of
untreated groups on day 4, demonstrating a significant inhibition of cell
viability in p53-null HCT 116 cells by treating with PTK7 siRNA
(Fig. 6B). And in a BrdU incorporation experiment, silencing of PTK7
significantly inhibited BrdU incorporation in p53-null HCT 116 cells,
s u g ge s t i n gadi re cte f f e c to fP T K7p ro t ein oncell proliferation (Fig.6C).
On the other hand, the Annexin V/PI staining experiment showed
Figure 6. PTK7 expression and cell apoptosis induced by knocking down of PTK7 in p53-null HCT 116 cells. (A) Flow cytometry assay
for the binding of the PE-labeled anti-PTK7 with p53-null HCT 116 cells (Grey curves). The black curves represent the background binding of anti-IgG-
PE. The concentration of the antibody in the binding buffer was 2 mg/mL. (B) The number of live p53-null HCT 116 cells was counted on day 4 after
treatment with vehicle, nonspecific siRNA and PTK7 siRNA. Data are mean6s.d. of three independent experiments. *Student’s t-test: P,0.05. (C) BrdU
incorporation relative to untreated cells detected by flow cytometry. p53-null HCT 116 Cells were incubated with 10 mM BrdU for 2 h after 48 h of
treatment. The amount of BrdU incorporation was normalized to the untreated group. Data are mean6s.d. of three independent experiments.
*Student’s t-test: P,0.05. (D) Apoptosis occurrence in p53-null HCT 116 cells detected by Annexin V/PI stain on days 4 after transfection. Cells stained
negative for both Annexin V and PI were considered healthy and percentage was shown in the figure.
doi:10.1371/journal.pone.0014018.g006
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increase in apoptotic and dead cells on day 4 compared with untreated,
vehicle, and nonspecific siRNA control groups.
The apoptosis induced by PTK7 knockdown has been proved
to be caspase-10 dependent in wild type HCT 116. So the
apoptosis pathway in p53-null HCT 116 induced by PTK7
knockdown was further investigated. JC-1 experiment was
monitored by both fluorescence microscopy (Fig. 7A) and flow
cytometry (Fig. 7B). Clearly, mitochondrial membrane potential
decreased in p53-null HCT 116 cells treated with PTK7 siRNA.
At the same time, a caspase inhibitor experiment was carried out
using p53-null HCT 116 cells. As shown in Fig. 7C, pancaspase
inhibitor or caspase-10 inhibitor treatment inhibited the apoptosis
induced by PTK7 knockdown compared to all other inhibitors,
which indicated the apoptosis in p53-null HCT 116 cells induced
by PTK7 knockdown was caspased-10 dependent.
Discussion
The present work demonstrates that RNAi suppression of
PTK7 induces caspase-10-dependent apoptosis in both wild type
and p53-null HCT 116 cells. Small interfering RNA is a very
Figure 7. Mitochondria and caspase-10 involvement in the apoptosis induced by knocking down of PTK7 in p53-null HCT 116 cells.
(A) Fluorescence microscope detection of mitochondrial membrane potential in treated p53-null HCT 116 cells. (B) Flow cytometry detection of
mitochondrial membrane potential in treated p53-null HCT 116 cells. (C) Cell viability after incubation with caspase inhibitors prior to transfaction of
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through sequence-specific degradation of target mRNA. This
study showed that siRNA efficiently suppressed PTK7 expression
at the level of both mRNA and protein. A nonspecific siRNA was
used as a negative control to confirm that suppression of PTK7
was the result of the specific silencing effect of PTK7 siRNA.
After confirming suppression of PTK7 by siRNA, we then
considered whether the inhibition of PTK7 would affect cell
viability and proliferation. Trypan Blue Exclusion Assay showed
that the number of live HCT 116 cells transfected with PTK7
siRNA was remarkably less than that of the control groups on day
4. Compared to nonspecific siRNA group as negative control, it
was clear that suppression of PTK7 accounted for the inhibition of
cell viability. To assess the effect of PTK7 knockdown on HCT
116 cell proliferation, a BrdU incorporation experiment was
performed to measure DNA synthesis. Interestingly, PTK7 silenci-
ng significantly inhibited BrdU incorporation in HCT 116 cells,
indicating that knock down of PTK7 expression had a direct effect
on HCT 116 cell growth. In fact, PTK7 has been identified as a
gene expressed in primary colon carcinoma, and overexpression of
PTK7 is often found in colon carcinoma cells. Furthermore, knock
down of PTK7 induced HCT 116 cell apoptosis, verified through
Annexin V/PI stain. After knock down of PTK7, ratios of
apoptotic HCT 116 cells revealed by Annexin V/PI stain showed
a large increase of percentage of apoptotic HCT 116 cells. These
results provide evidence that suppression of PTK7 can signifi-
cantly increase the occurrence of apoptosis in HCT 116 cells, and
that an excess of PTK7 can be associated with resistance of cancer
cells to induction of cell death.
The results further demonstrated that knock down of PTK7
caused a large decrease in mitochondrial membrane potential of
HCT 116 cells, suggesting that mitochondrial dysfunction may be
involved in this apoptosis, and that the mitochondrial pathway to
cell death may play an important role in apoptosis induced by
knock down of PTK7. Caspase-9 was also activated after PTK7
siRNA treatment in HCT 116 cells. At the same time, apoptosis
inhibition experiments showed that caspase-10 also plays a critical
role in apoptosis induced by knock down of PTK7 in HCT 116
cells. Interestingly, caspase-8 inhibitor had no effect on this
apoptosis at all, even though it has always been thought that
caspase-8 and caspase-10 play identical roles in the extrinsic
pathway to cell death. Western blot was used to examine the
procaspase-8, -10 and active caspase-8 levels in PTK7 siRNA-
treated HCT 116 cells. Procaspase-10 level changes were obvious,
but active caspase-8 was not detectable (data not shown).
Additionally, Bid/t-Bid level changes were examined, and no t-
Bid was found (Fig. 5A) indicating that there was no signal transfer
from the extrinsic pathway to the intrinsic pathway. Thus, the
extrinsic pathway was not involved as reported by Filomenko P.
et al.[20].
Furthermore, p53-null HCT 116 cells were used to study the
involvement of p53 in the apoptosis induced by PTK7
knockdown. When treated with PTK7 siRNA, cell proliferation
decreased and apoptosis increased in p53-null HCT 116 cells.
Also, mitochondria were involved in the apoptosis, which was
caspase-10 dependent. When comparing the results between wild
type HCT 116 and p53-null HCT 116, PTK7 knockdown had less
effect on cell proliferation and apoptosis in p53-null HCT 116
cells, but the apoptosis induced by PTK7 knockdown was caspase-
10 dependent in both cell lines. Therefore, the effect of PTK7
knockdown on cell apoptosis was p53 related but not dependent.
Altogether, the results show that the knock down of PTK7 in
wild type HCT 116 cells and p53-null HCT 116 cells induces cell
apoptosis and affects cell proliferation. Also, caspase-10 activation
plays a critical role in the caspase cascade, downstream of
mitochondria after knock down of PTK7.
Conclusion
In conclusion, suppression of PTK7 significantly increases
apoptosis and inhibits cell proliferation in HCT 116 cells,
indicating that PTK7 may play an important role in maintaining
cancer cell viability. Apoptosis induced by knock down of PTK7
was caspase-10-dependent, and caspase-10 activation was down-
stream of mitochondria. Therefore, the use of PTK7 siRNA, or
other methods that counteract PTK7 function, may be valuable in
the development of cancer therapeutic agents.
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